HSBC lowered the firm’s price target on Bristol Myers to $45 from $50 and keeps a Hold rating on the shares post the Q1 report. The company’s capital allocation and life-cycle management strategy for Opdivo “might help ease the pain,” the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Bristol Myers enters multi-year strategic collaboration with Repertoire
- Bristol Myers price target lowered to $55 from $60 at BofA
- Bristol Myers announces EMA’s CHMP recommended approval of Opdivo
- Bristol Myers price target lowered to $43 from $51 at Barclays
- Massive Job Cuts Send Bristol-Myers Squibb (NYSE:BMY) into Tailspin
